Evidence map›Paper›PMID 30004254›Full record

ArticleJournal of child and adolescent psychopharmacology2018

Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study.

Kathryn R Cullen, Palistha Amatya, Mark G Roback, Christina Sophia Albott, Melinda Westlund Schreiner, Yanan Ren, Lynn E Eberly, Patricia Carstedt, Ali Samikoglu, Meredith Gunlicks-Stoessel and 5 more

Erratum issued Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of child and adolescent psychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06957704 (Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents), which is not on this map. Cited by 43 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 4 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06957704 phase3not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents

TypeinterventionalSponsorFederal University of São PauloRan2025 to 2028Enrolled60ConditionsDepressive Disorder, Suicidal IdeasArmsketamine, Midazolam
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 4 syntheses or guidelines pooled it, 112 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression.Journal of child and adolescent psychopharmacology · 2024
    Trial
  9. Trial
  10. Ketamine or Esketamine in Special Populations of Patients With Treatment-Resistant Depression.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Kathryn R Cullen1 Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Minnesota Medical School , Minneapolis, Minnesota.
Palistha Amatya1 Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Minnesota Medical School , Minneapolis, Minnesota.
Mark G Roback2 Departments of Pediatrics and Emergency Medicine, Medical School, University of Minnesota , Minneapolis, Minnesota.
Christina Sophia Albott1 Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Minnesota Medical School , Minneapolis, Minnesota.
Melinda Westlund Schreiner3 Psychology Department, College of Liberal Arts, University of Minnesota , Minneapolis, Minnesota.
Yanan Ren4 Division of Biostatistics, School of Public Health, University of Minnesota , Minneapolis, Minnesota.
Lynn E Eberly4 Division of Biostatistics, School of Public Health, University of Minnesota , Minneapolis, Minnesota.
Patricia Carstedt1 Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Minnesota Medical School , Minneapolis, Minnesota.
Ali Samikoglu5 Hennepin County Medical Center , Minneapolis, Minnesota.
Meredith Gunlicks-Stoessel1 Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Minnesota Medical School , Minneapolis, Minnesota.
Kristina Reigstad1 Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Minnesota Medical School , Minneapolis, Minnesota.
Nathan Horek1 Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Minnesota Medical School , Minneapolis, Minnesota.
Susannah Tye6 Mayo Clinic , Rochester, Minnesota.
Kelvin O Lim1 Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Minnesota Medical School , Minneapolis, Minnesota.
Bonnie Klimes-Dougan3 Psychology Department, College of Liberal Arts, University of Minnesota , Minneapolis, Minnesota.
University of Minnesota · USHennepin County Medical Center · USMayo Clinic · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
NMR Imaging and SpectroscopyP41EB015894 · NIBIB · UNIVERSITY OF MINNESOTA · PI UGURBIL, KAMIL · 2012 to 2017
$8.4M
Institutional Center Cores for Advanced NeuroimagingP30NS076408 · NINDS · UNIVERSITY OF MINNESOTA · PI UGURBIL, KAMIL · 2012 to 2020
$4.2M
High Performance Connectome Upgrade for Human 3T MR ScannerS10OD017974 · OD · UNIVERSITY OF MINNESOTA · PI LIM, KELVIN O. · 2014 to 2014
$600k
NCATS NIH HHS UL1 TR002494NIBIB NIH HHS P41 EB015894NIH HHS S10 OD017974NINDS NIH HHS P30 NS076408
6 · The paper itself

Abstract

backgroundNovel interventions for treatment-resistant depression (TRD) in adolescents are urgently needed. Ketamine has been studied in adults with TRD, but little information is available for adolescents. This study investigated efficacy and tolerability of intravenous ketamine in adolescents with TRD, and explored clinical response predictors.

methodsAdolescents, 12-18 years of age, with TRD (failure to respond to two previous antidepressant trials) were administered six ketamine (0.5 mg/kg) infusions over 2 weeks. Clinical response was defined as a 50% decrease in Children's Depression Rating Scale-Revised (CDRS-R); remission was CDRS-R score ≤28. Tolerability assessment included monitoring vital signs and dissociative symptoms using the Clinician-Administered Dissociative States Scale (CADSS).

resultsThirteen participants (mean age 16.9 years, range 14.5-18.8 years, eight biologically male) completed the protocol. Average decrease in CDRS-R was 42.5% (p = 0.0004). Five (38%) adolescents met criteria for clinical response. Three responders showed sustained remission at 6-week follow-up; relapse occurred within 2 weeks for the other two responders. Ketamine infusions were generally well tolerated; dissociative symptoms and hemodynamic symptoms were transient. Higher dose was a significant predictor of treatment response.

conclusionsThese results demonstrate the potential role for ketamine in treating adolescents with TRD. Limitations include the open-label design and small sample; future research addressing these issues are needed to confirm these results. Additionally, evidence suggested a dose-response relationship; future studies are needed to optimize dose. Finally, questions remain regarding the long-term safety of ketamine as a depression treatment; more information is needed before broader clinical use.

Indexed as

Administration, IntravenousAdolescentChildDepressive Disorder, Treatment-ResistantDose-Response Relationship, DrugExcitatory Amino Acid AntagonistsFemaleHumansKetamineMalePsychiatric Status Rating ScalesExcitatory Amino Acid AntagonistsKetamineadolescentdepressionketaminetreatment-resistant

Identifiers

PMID30004254
PMCPMC6154760
OpenAlexW2884469025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.